Department of Gastroenterological Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Department of Infectious Disease, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Ann Surg Oncol. 2022 Nov;29(12):7448-7457. doi: 10.1245/s10434-022-12166-z. Epub 2022 Jul 14.
Although accumulating evidence suggests that an imbalanced gut microbiota leads to cancer progression, few studies demonstrated the implication in patients who underwent oncologic esophagectomy. This study aimed to elucidate the association between gut microbes and the outcomes after oncologic esophagectomy, as well as the host's inflammatory/nutritional status.
Overall, 783 consecutive patients who underwent oncologic esophagectomy were eligible. We investigated the microbiota detected by fecal culture tests and then assessed the association between the gut microbiota and patient characteristics, short-term outcomes, and long-term survival.
Seventeen different species could be cultivated. We comprehensively examined the impact of each detected microbe on survival. The presence of Bacillus species (Bacillus sp.; 26.8%) was associated with favorable prognosis on overall and cancer-specific survival (p = 0.02 and 0.02, respectively). Conversely, the presence of Proteus mirabilis (P. mirabilis; 3.4%) was associated with unfavorable overall and recurrence-free survivals (p = 0.02 and < 0.01, respectively). Multivariate analysis showed that the presence of P. mirabilis was one of the independent prognostic factors for poor recurrence-free survival (p < 0.01). Patients with Bacillus sp. had lower modified Glasgow prognostic score and better response to preoperative treatment than those without (p = 0.01 and 0.03, respectively). Meanwhile, patients with P. mirabilis were significantly associated with higher systemic inflammation scores and increased postoperative pneumonia incidence than those without (p = 0.01 and 0.02, respectively).
Preoperative fecal microbiota was associated with the host's inflammatory and nutritional status and may influence the outcomes after oncologic esophagectomy.
尽管越来越多的证据表明肠道微生物群失衡会导致癌症进展,但很少有研究表明这种失衡在接受肿瘤食管切除术的患者中存在。本研究旨在阐明肠道微生物群与肿瘤食管切除术后结局之间的关系,以及宿主的炎症/营养状况。
共有 783 例连续接受肿瘤食管切除术的患者符合条件。我们调查了粪便培养试验检测到的微生物群,然后评估了肠道微生物群与患者特征、短期结局和长期生存之间的关系。
可培养出 17 种不同的物种。我们全面检查了每种检测到的微生物对生存的影响。芽孢杆菌属(Bacillus sp.;26.8%)的存在与总生存和癌症特异性生存相关(p=0.02 和 0.02)。相反,奇异变形杆菌(P. mirabilis;3.4%)的存在与总生存和无复发生存相关(p=0.02 和 <0.01)。多变量分析显示,P. mirabilis 的存在是无复发生存不良的独立预后因素之一(p<0.01)。与无芽孢杆菌属的患者相比,芽孢杆菌属的患者具有较低的改良格拉斯哥预后评分和对术前治疗的更好反应(p=0.01 和 0.03)。同时,与无奇异变形杆菌的患者相比,有奇异变形杆菌的患者与更高的全身炎症评分和术后肺炎发生率显著相关(p=0.01 和 0.02)。
术前粪便微生物群与宿主的炎症和营养状况有关,并可能影响肿瘤食管切除术后的结局。